Iridium Stockholders Approve Acquisition by Rocket Lab

Iridium shareholders approved Rocket Lab's acquisition of Iridium, with 99.6% of votes cast in favor, representing 81.0% of outstanding shares eligible to vote. Iridium holders will receive $27.00 in cash plus Rocket Lab shares under a collar-based exchange ratio, implying a notional value of $54.00 per Iridium share. The deal is targeted to close by mid-2027, subject to regulatory approvals and customary conditions, combining Iridium's global satellite network and spectrum with Rocket Lab's launch and space-systems capabilities.

Analysis

The shareholder vote removes a low-probability closing obstacle but does not materially de-risk the variables that should determine the merger spread: financing terms, FCC/national-security review, and the treatment of sensitive government and spectrum-linked contracts. IRDM should increasingly trade as a collar-defined claim on RKLB plus cash rather than on standalone operating results; until the final exchange ratio, collar boundaries, termination provisions, and expected close-date discount rate are modeled from the merger proxy, apparent upside to the stated consideration is not actionable arbitrage alpha. The likely near-term effect is lower IRDM idiosyncratic volatility and higher beta to RKLB.

For RKLB, the market is likely to reward the strategic narrative before it prices the capital-allocation burden. A recurring, cash-generative communications asset can lower the combined entity's perceived funding risk and support a higher multiple over 6-18 months, but only if it does not divert capital from Neutron and defense execution. The less appreciated downside is that a stock-funded component makes RKLB's valuation itself a closing risk: a sustained RKLB drawdown can force IRDM holders to reprice consideration, while debt financing at wider spreads would reduce the claimed diversification benefit. This is not a clean read-through to ASTS, GSAT, or VSAT: a vertically integrated competitor with spectrum and government customer access raises strategic pressure, but regulatory conditions or customer-retention friction could leave those peers with a longer runway than consensus assumes.

Consensus may overstate what the vote signals. It validates the negotiated price, not the synergy case or the regulatory timetable; a mid-2027 close leaves multiple quarterly windows for launch delays, rate volatility, defense-budget shifts, and integration leakage. Falsify the cautious RKLB view if management provides committed financing with limited dilution, reiterates Neutron milestones, and quantifies post-close leverage/FCF accretion; conversely, any extension in agency review, financing-cost increase, or reduction in RKLB's development cadence should widen the IRDM spread and compress RKLB's multiple.

Key Decisions for Investors

• Do not initiate a standalone IRDM merger-arbitrage position until the definitive exchange-ratio collar, financing commitments, and termination fee are extracted from the proxy; then buy IRDM only if the annualized gross spread exceeds 12-15% after hedging the stock component with RKLB.
• For a modeled collar hedge, use long IRDM / short the exact RKLB share equivalent only when IRDM's implied deal value is at least 5% below the collar-adjusted consideration; reassess immediately if regulatory timing extends beyond mid-2027 or RKLB financing spreads widen.
• Maintain RKLB exposure at a reduced weight into financing disclosure rather than chase the vote-driven reaction. Add over a 1-3 month horizon only on evidence of committed funding and unchanged Neutron milestones; trim or hedge with RKLB puts if the transaction requires materially greater equity issuance or incremental debt than modeled.
• Watch ASTS, GSAT, and VSAT for relative-value opportunities after merger terms are clarified: short only against a long RKLB/IRDM exposure if the combined company receives approvals without meaningful spectrum, security, or customer-contract conditions. Absent that data, competitive-displacement trades are premature.